sabcomeline and Tremor

sabcomeline has been researched along with Tremor* in 2 studies

Other Studies

2 other study(ies) available for sabcomeline and Tremor

ArticleYear
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects.
    Brain research, 1998, Jun-08, Volume: 795, Issue:1-2

    Activation of muscarinic m1 receptors which are coupled to the phosphoinositide (PI) second messenger transduction system is the initial objective of cholinergic replacement therapy in Alzheimer's disease. Thus, we evaluated the ability of the selective muscarinic receptor agonist (SMRA) xanomeline to stimulate in vivo phosphoinositide (PI) hydrolysis and compared it to a number of direct acting muscarinic agonists, two cholinesterase inhibitors and a putative m1 agonist/muscarinic m2 antagonist. Using a radiometric technique, it was determined that administration of xanomeline robustly stimulated in vivo PI hydrolysis and the effect was blocked by muscarinic antagonists, demonstrating mediation by muscarinic receptors. The non-selective muscarinic agonists pilocarpine, oxotremorine, RS-86, S-aceclidine, but not the less active isomer R-aceclidine, also effectively stimulated PI hydrolysis in mice. Amongst the putative m1 agonists, thiopilocarpine, hexylthio-TZTP as well as xanomeline effectively stimulated PI hydrolysis, but milameline, WAL 2014, SKB 202026 and PD 142505 did not significantly alter PI hydrolysis. Furthermore, WAL 2014 and SKB 202026 inhibited agonist-induced PI stimulation, suggesting that they act as antagonists at PI-coupled receptors in vivo. The cholinesterase inhibitors, tacrine and physostigmine, and the mixed muscarinic m1 agonist/m2 antagonist LU25-109 did not activate in vivo PI hydrolysis. Xanomeline, hexylthio-TZTP and thiopilocarpine were relatively free of cholinergic side effects, whereas milameline, WAL 2014 and SKB 202026 produced non-selective effects. Therefore, these data demonstrate that xanomeline selectively activates in vivo PI hydrolysis, consistent with activation of biochemical processes involved in memory and cognition and xanomeline's beneficial clinical effects on cognition in Alzheimers patients.

    Topics: Animals; Binding, Competitive; Brain Chemistry; Bridged Bicyclo Compounds, Heterocyclic; Cholinergic Agents; Cholinesterase Inhibitors; Dihydropyridines; Dose-Response Relationship, Drug; Hydrolysis; Hypothermia; Imines; Lithium; Male; Mice; Mice, Inbred Strains; Muscarinic Agonists; Oximes; Parasympathomimetics; Phosphatidylinositols; Physostigmine; Pilocarpine; Pyridines; Quinuclidines; Radioligand Assay; Salivation; Tacrine; Tetrazoles; Thiadiazoles; Tremor

1998
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
    Journal of medicinal chemistry, 1997, Dec-19, Volume: 40, Issue:26

    Loss of cholinergic function is believed to be implicated in the cognitive decline associated with senile dementia of the Alzheimer type (SDAT). The disease is characterized by progressive loss of muscarinic receptors located on nerve terminals while postsynaptic muscarinic M1 receptors appear to remain largely intact. Muscarinic agonists acting directly on postsynaptic receptors offer the prospect of countering the cholinergic deficit in SDAT. This study describes a novel series of azabicyclic muscarinic agonists, which incorporate an oxime ether or modified oxime ether group as an ester bioisostere. Modification of the oxime ether function by the introduction of electron withdrawing groups led to the finding that the (Z)-N-methoxy imidoyl nitrile group serves as a stable methyl ester bioisostere. This culminated in the discovery of the quinuclidinyl N-methoxy imidoyl nitrile R-(+)-(Z)-5g which is a functionally selective muscarinic M1 partial agonist currently in phase III clinical trials for the treatment of SDAT. The selective profile of R-(+)-(Z)-5g can be rationalized in terms of the relative affinity of the compound at muscarinic receptor subtypes, the degree of agonist efficacy, and brain penetrancy.

    Topics: Alzheimer Disease; Animals; Binding Sites; Blood Pressure; Brain; CHO Cells; Cricetinae; Electroencephalography; Heart Rate; Humans; Imines; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Molecular Structure; Muscarinic Agonists; Protein Binding; Quinuclidines; Rats; Rats, Inbred Strains; Receptor, Muscarinic M1; Receptors, Muscarinic; Recombinant Proteins; Stereoisomerism; Tremor

1997